| Our data demonstrate a tumor suppressor effect of miR-17-92a cluster miRNAs in prostate cancer cells and restoration of expression of these miRNAs has a therapeutic benefit for both androgen-dependent and -independent prostate cancer cells. | prostate, |
| miR-17~92 is a powerful cancer driver that coordinates the activation of multiple oncogenic pathways in lymphomagenesis | lymphoma, |
| The oncogenic miR-17-92 cluster is involved in cutaneous B-cell lymphoma progression. | lymphoma, |
| these findings indicate that SLU7 is co-opted by hepatocellular carcinoma (HCC) cells and other tumor cell types to maintain survival, and identify this splicing regulator as a new determinant for the expression of the oncogenic miR-17-92 cluster. This novel mechanism may be exploited for the development of antitumoral strategies in cancers displaying such SLU7-miR-17-92 crosstalk. | liver, |
| miR-19 is a key oncogenic component of mir-17-92. | None |
| Human GAM/ZFp/ZNF512B is part of a regulatory network with cell-cycle regulators, TGF-beta effectors and miR-17-92 cluster oncogenic miRNAs. | None |
| The structural complexity of mir-17-92 as a polycistronic miRNA oncogene, along with the complex mode of interactions among its components, constitutes the molecular basis for its unique functional complexity during normal and tumor development.[Review] | None |
| vFLIP and vCyclin induce the oncogenic miR-17-92 cluster in endothelial cells | None |
| Data show the potential of microRNA miR-17-92 for oncogenesis regulation in stem cells. | None |